Radiopharmaceutical · developed by Radiopharm Theranostics
161Tb RAD402 is a radiopharmaceutical labeled with the radioisotope terbium-161.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07259213 | Phase 1/2 | Castration-resistant Prostate Cancer | Recruiting | RADX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-resistant Prostate Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.
See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RADX catalysts and pipeline →